AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02117401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
Study NCT02577809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine100
Description: 100mcg added to the spinal anaesthetic
Study NCT02577809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine50
Description: 50mcg added to the spinal anaesthetic
Study NCT02577809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25mcg Fentanyl added to the spinal anaesthetic
Study NCT01040793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of low and high dose and placebo on exercise endurance time in COPD patients
Study NCT01040793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744)
Description: Comparison of low and high dose on exercise endurance time in COPD patients
Study NCT01040793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) placebo
Description: Placebo that represents olodaterol
Study NCT02166853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Sedation with inhaled sevoflurane
Study NCT02166853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Sedation with intravenous midazolam
Study NCT05141630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy or targeted axillary dissection alone
Description: sentinel lymph node biopsy or targeted axillary dissection alone
Study NCT01560819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gut Microbial Transplantation
Description: Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
Study NCT04096339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy followed by EGD
Description: Colonoscopy is done first followed by EGD
Study NCT04096339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EGD followed by Colonoscopy
Description: Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
Study NCT02851719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT with biofeedback + Home PFMT
Description: 24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
Study NCT02851719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT without biofeedback + Home PFMT
Description: 24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
Study NCT02968719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil TDS Version A
Description: Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
Study NCT02968719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version A
Description: Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
Study NCT02968719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil TDS Version B
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
Study NCT02968719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version B
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
Study NCT02968719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept
Description: Aricept (5 mg and 10 mg) Donepezil Hydrochloride
Study NCT02968719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version D
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
Study NCT02577809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Bupivicaine
Description: 1.8ml 0.5% spinal bupivicaine with dextrose
Study NCT02106975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Intervention
Study NCT03255291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Recording - Sleep
Description: -Participants imagine themselves improving sleep hygiene
Study NCT03255291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.
Study NCT02968719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS Version E
Description: Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
Study NCT02577809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: 100mg Indomethacin suppository
Study NCT02106975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 5% Dextrose in water
Description: Placebo
Study NCT01132365 — intervention group
Intervention type: DEVICE
Intervention: any knee joint arthroplasty device
Description: Cohort consist of all consented patients receiving knee arthroplasty
Study NCT01307982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fundoplication
Description: During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
Study NCT02009709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 0.1% ophthalmic solution
Description: Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
Study NCT01307982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrojejunal (GJ) feeding tube
Description: Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
Study NCT00352339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rispridoen and Aripiprazole
Description: Start with risperidone and switch it to aripiprazole. Flexible dose
Study NCT00352339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidne
Description: Start with risperidne and keep it through the end of study. Risperidne:flexible dose
Study NCT00352339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abilify
Description: Start with abilify and keep it through the end of study
Study NCT03951155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation
Description: * Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~* Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~* Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~* Finally, ask him/her to notice how his/her muscles feel after the exercise.
Study NCT00400764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulanermin
Description: Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
Study NCT00400764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
Study NCT00400764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
Study NCT04198012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoCare™ Hemodialysis System
Description: The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
Study NCT01417767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG regimen
Description: cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
Study NCT01417767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-aza-deoxycytidine
Description: Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
Study NCT01245608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
Study NCT04349969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
Study NCT04349969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117+AK104
Description: All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
Study NCT04049513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WZTL002-1 (1928T2z CAR-T cells)
Description: WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
Study NCT04049513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
Description: Cyclophosphamide 500 mg/m\^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m\^2 IV on days -5 to -3, inclusive
Study NCT02239003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Study NCT02009709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CCL-VARIO UV lamp
Description: Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
Study NCT02009709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CCL-VARIO at 18 mW/cm2
Description: Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
Study NCT02239003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00514189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells
Description: The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
Study NCT02527512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
Study NCT02527512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
Study NCT03917615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor contraction
Description: Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
Study NCT03917615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor contraction
Description: Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
Study NCT01859013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
Study NCT01859013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
Study NCT01542892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
Study NCT01542892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Supplement Intervention
Description: Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
Study NCT01542892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement Intervention
Description: Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
Study NCT02978495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorrubicin 60 mg/m2 4 cycles each 21 days
Study NCT02978495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorrubicin 60 mg/m2 4 cycles each 21 days
Study NCT02978495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 1,5 once a week, for 12 weeks
Study NCT02978495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 weekly for 12 weeks
Study NCT02978495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 weekly for 12 weeks
Study NCT02117401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
Study NCT02978495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 4 cycles each 21 days
Study NCT02978495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600mg/m2 4 cycles each 21 days
Study NCT03333187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Study NCT03333187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib continuous therapy
Study NCT00244985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV
Study NCT00244985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: IV
Study NCT03325231 — intervention group
Intervention type: OTHER
Intervention: Reconstructive surgery following bladder removal.
Description: Investigating patient experience of bladder reconstructions.
Study NCT02329587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERP plus tDCS
Description: Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
Study NCT02329587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERP plus sham tDCS
Description: Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
Study NCT02457065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melanoma Survivor plaque
Description: The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
Study NCT01554904 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Facial-Flex
Description: Oral exercise device
Study NCT00654355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: tacrolimus ointment to be applied twice daily to affected areas during duration of study
Study NCT01940055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual task treadmill walking exercise program
Description: Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
Study NCT01940055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual task recumbent cycling exercise program
Description: Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
Study NCT02553096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACCESS
Description: The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
Study NCT04164927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymphatic Drainage
Description: 1. Lymphatic correction method was used via the KinesioTaping® to patients group.~2. Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~3. Control group received only physiotherapy treatment.
Study NCT04164927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.
Study NCT04164927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
Study NCT03161873 — intervention group
Intervention type: DEVICE
Intervention: Ava
Description: Ava is a fertility monitoring bracelet that collects various physiological parameters
Study NCT02305992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Block with 0.5% Ropivicaine
Description: Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.